Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but ...

Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites seeding new resistant tumors elsewhere in the body. Combating the problem has ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...

Cancer cells often survive treatment by fixing the DNA damage that therapy is meant to cause. Researchers found that UNI418 ...

The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

Laboratory studies suggest cinnamon’s bioactive compounds can alter key cancer-related signaling pathways, but researchers caution that human trials are essential before any preventive or therapeutic ...

What if a new combination of cancer drugs could sound an alarm, alerting the body's immune system to invoke a targeted ...

Mitochondrial defects are associated with the development of diseases such as type 2 diabetes (T2D). Studies in mice and in human tissues, by researchers at the University of Michigan, have now found ...